IMPLEMENTATION LEVEL

Subnational

AFFECTED FLOW

Inflow

ANNOUNCED AS TEMPORARY

No

NON-TRADE-RELATED RATIONALE

No

ELIGIBLE FIRMS

firm-specific

JUMBO

No

TARIFF PEAK

No
← back to the state act
Inception date: 01 May 2012 | Removal date: open ended
Still in force

Tax or social insurance relief

In 2012 state and local governments in Georgia provided an incentive package to Baxter International for a pharmaceutical manufacturing facility. The value was estimated by The Atlanta Journal-Constitution based on the Economic Development Agreement Between Baxter and the State of Georgia.
State level subsidies include: at least $27.2 million in sales tax exemptions on machinery and equipment; a $28.1 million Quality Jobs tax credit; $14 million for a training facility; a $13.8 million infrastructure grant; $10.4 million in Quick Start job training funds; a $4.7 million Jobs tax credit; a $2.5 million sales tax exemption on construction materials; $1.47 million in job training funds from Georgia Works Ready; a $1.35 million energy sales tax exemption; and $150,000 from the Georgia Department of Labor for a recruitment center.
 
Local subsidies include: 15-year real and personal property tax abatements worth $94.1 million; a site worth $6.5 million; a $5.9 million grant for a new wastewater treatment plant; $1.3 million in waived fees; $100,000 for road improvements; $60,000 for use of authority offices; and unknown amount in Freeport tax exemptions and costs associated with industrial development bonds. 
 
The GTA includes state guarantees and other financial incentives thatare likely to affect the restructuring and performance of firms facinginternational competition, whether from imports, in export markets, andfrom foreign subsidiaries.
 
As no official source could be obtained, this measure is coded "amber".

AFFECTED COUNTRIES

MAP
TABLE
EXPORT

AFFECTED SECTORS AND PRODUCTS

352 Pharmaceutical products
3002 Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micr
300210 Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes
300220 Vaccines for human medicine
300230 Vaccines for veterinary medicine
300290 Other
3003 Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.
300310 Containing penicillins or derivatives thereof, with a penicillanic acid structure, or streptomycins or their derivatives
300320 Containing other antibiotics
300339 Other
300340 Containing alkaloids or derivatives thereof but not containing hormones or other products of heading 29.37 or antibiotics
300390 Other
3004 Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packin
300410 Containing penicillins or derivatives thereof, with a penicillanic acid structure, or streptomycins or their derivatives
300420 Containing other antibiotics
300431 Containing insulin
300432 Containing corticosteroid hormones, their derivatives or structural analogues
300439 Other
300440 Containing alkaloids or derivatives thereof but not containing hormones, other products of heading 29.37 or antibiotics
300450 Other medicaments containing vitamins or other products of heading 29.36
300490 Other

Please report this page in case you detect an inaccuracy in its content.